글로벌 건선 치료 시장, 약물 종류별(코르티코스테로이드, TNF 억제제, 인터루킨, 기타), 유형별(반점형 건선, 건선성 관절염, 기타), 투여 경로(경구, 비경구, 국소), 적용 분야(국소 치료제, 전신 치료제, 복합제), 최종 사용자(병원 약국, 진료소, 소매 약국, 온라인 판매), 국가별(미국, 캐나다, 멕시코, 페루, 브라질, 아르헨티나, 남미 기타 지역, 독일, 이탈리아, 영국, 프랑스, 스페인, 네덜란드, 벨기에, 스위스, 터키, 러시아, 헝가리, 리투아니아, 오스트리아, 아일랜드, 노르웨이, 폴란드, 유럽 기타 지역, 일본, 중국, 인도, 한국, 호주, 싱가포르, 말레이시아, 태국, 인도네시아, 필리핀, 베트남, 아시아 태평양 기타 지역, 남아프리카 공화국, 사우디 아라비아, UAE, 쿠웨이트, 이스라엘, 이집트, 중동 및 아프리카 기타 지역) 산업 동향 및 2029년까지의 예측.
시장 분석 및 통찰력 글로벌 건선 치료 시장
건선 치료 시장은 2022년부터 2029년까지 예측 기간 동안 7.85%의 시장 성장률을 기록할 것으로 예상됩니다. Data Bridge Market Research의 건선 치료 시장 보고서는 예측 기간 동안 만연할 것으로 예상되는 다양한 요인에 대한 분석과 통찰력을 제공하고, 이러한 요인들이 시장 성장에 미치는 영향을 분석합니다. 전 세계적으로 만성 질환 유병률이 증가함에 따라 건선 치료 시장 성장도 가속화되고 있습니다.
건선은 신체의 전신적인 증상과 관련이 있는 만성 염증성 피부 질환입니다. 이 유전적 질환은 선천적으로 나타날 수도 있고 그렇지 않을 수도 있지만, 유전적 및 환경적 요인에 의해 유발될 수도 있습니다.
전 세계적으로 건선 유병률 증가는 건선 치료 시장 성장을 견인하는 주요 요인 중 하나입니다. 제조업체 간 협력 증가와 치료에 대한 인식 제고는 시장 성장을 가속화합니다. 신흥 경제국에서 건선 치료제에 대한 질병 부담과 수요 증가, 그리고 정부의 적극적인 지원 정책은 시장에 더욱 큰 영향을 미치고 있습니다. 또한, 기술 발전 , 인구 증가, 치료 개선을 위한 연구 개발 확대, 그리고 의료비 지출 급증은 건선 치료 시장에 긍정적인 영향을 미칩니다. 나아가, 건선 연구 및 파이프라인 약물의 증가는 2022년부터 2029년까지의 예측 기간 동안 시장 참여자들에게 수익성 있는 기회를 확대할 것입니다.
반면, 약물 개발 및 대부분의 치료법과 관련된 높은 비용은 시장 성장을 저해할 것으로 예상됩니다. 약물 승인 지연은 2022년에서 2029년 예측 기간 동안 건선 치료 시장에 어려움을 줄 것으로 예상됩니다.
이 건선 치료 시장 보고서는 최근 동향, 무역 규제, 수출입 분석, 생산 분석, 가치 사슬 최적화, 시장 점유율, 국내 및 현지 시장 참여자의 영향, 신규 매출 창출 기회 분석, 시장 규제 변화, 전략적 시장 성장 분석, 시장 규모, 카테고리별 시장 성장, 적용 분야 및 시장 점유율, 제품 승인, 제품 출시, 지리적 확장, 시장 기술 혁신 등에 대한 자세한 정보를 제공합니다. 건선 치료 시장에 대한 더 자세한 정보는 Data Bridge Market Research for an Analyst Brief 에 문의 해 주십시오. 저희 팀은 시장 성장을 위한 정보에 기반한 시장 결정을 내릴 수 있도록 도와드립니다.
글로벌 건선 치료 시장 범위 및 시장 규모
건선 치료 시장은 약물 종류, 유형, 투여 경로, 용도 및 최종 사용자를 기준으로 세분화됩니다. 각 세그먼트의 성장은 틈새 성장 영역과 시장 접근 전략을 분석하고 핵심 적용 분야와 목표 시장의 차이점을 파악하는 데 도움이 됩니다.
- 약물 종류에 따라 건선 치료 시장은 코르티코스테로이드 , TNF 억제제, 인터루킨 및 기타로 구분됩니다.
- 건선 치료 시장은 유형에 따라 플라크 건선, 건선성 관절염 및 기타로 구분됩니다.
- 투여 경로를 기준으로 건선 치료 시장은 경구, 비경구 , 국소로 구분됩니다.
- 건선 치료 시장은 적용 분야에 따라 국소 치료제, 전신 치료제 및 복합 치료제로 구분됩니다.
- 유통 채널을 기준으로 건선 치료 시장은 병원 약국, 진료소, 소매 약국 및 온라인 판매로 세분화됩니다.
건선 치료 시장 국가별 분석
건선 치료 시장을 분석하고, 위에 언급된 대로 국가, 약물 종류, 치료, 최종 사용자 및 유통 채널별로 시장 규모 정보를 제공합니다.
글로벌 건선 치료 시장 보고서에서 다루는 국가는 북미의 미국, 캐나다, 멕시코, 남미의 일부인 페루, 브라질, 아르헨티나 및 기타 남미, 독일, 이탈리아, 영국, 프랑스, 스페인, 네덜란드, 벨기에, 스위스, 터키, 러시아, 헝가리, 리투아니아, 오스트리아, 아일랜드, 노르웨이, 폴란드, 유럽의 기타 유럽, 일본, 중국, 인도, 한국, 호주, 싱가포르, 말레이시아, 태국, 인도네시아, 필리핀, 베트남, 아시아 태평양(APAC)의 기타 아시아 태평양(APAC), 남아프리카 공화국, 사우디 아라비아, UAE, 쿠웨이트, 이스라엘, 이집트, 중동 및 아프리카(MEA)의 일부인 기타 중동 및 아프리카(MEA)입니다.
북미 지역은 발달된 의료 인프라를 갖추고 있어 건선 치료 시장을 주도하고 있습니다. 아시아 태평양 지역은 인구 밀도가 높아 2022년부터 2029년까지 높은 성장세를 보일 것으로 예상됩니다.
보고서의 국가별 섹션은 개별 시장 영향 요인과 국내 시장 규제 변화도 제공하며, 이는 현재 및 미래 시장 동향에 영향을 미칩니다. 신규 매출, 교체 매출, 국가별 인구 통계, 질병 역학, 수출입 관세 등의 데이터는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 지표입니다. 또한, 글로벌 브랜드의 존재 및 가용성, 그리고 국내 및 국내 브랜드와의 경쟁이 심화되거나 부족하여 직면하는 과제, 판매 채널의 영향 등을 고려하여 국가별 데이터를 예측 분석합니다.
환자 역학 분석
건선 치료 시장은 환자 분석, 예후 및 치료에 대한 상세한 시장 분석도 제공합니다. 유병률, 발생률, 사망률, 순응도 등은 보고서에 포함된 데이터 변수 중 일부입니다. 시장 성장에 대한 역학의 직간접적 영향 분석을 통해 성장기의 시장 예측을 위한 더욱 견고하고 코호트 다변량 통계 모델을 구축합니다.
경쟁 환경 및 건선 치료 시장 점유율 분석
건선 치료 시장 경쟁 구도는 경쟁사별 세부 정보를 제공합니다. 여기에는 회사 개요, 회사 재무 상태, 매출 창출, 시장 잠재력, 연구 개발 투자, 신규 시장 진출, 글로벌 입지, 생산 시설 및 시설, 생산 능력, 회사의 강점과 약점, 제품 출시, 제품 종류 및 범위, 적용 분야별 우위 등이 포함됩니다. 위에 제공된 데이터는 해당 회사의 중점 분야인 건선 치료 시장에만 적용됩니다.
건선 치료 시장 보고서에서 활동하는 주요 기업으로는 Eli Lilly & Company, Pfizer Inc., Janssen Global Services LLC, Celgene Corporation, Takeda Pharmaceutical Company Limited, Novartis International AG, Amgen Inc., Biogen Inc., Abbvie Inc., AstraZeneca, Boeringer Ingelheim International GmbH, Biogen, Johnson & Johnson Services Inc., Merck & Co. Inc., Sun Pharmaceuticals Industries Ltd., Stiefel Laboratories, UCB SA, LEO Pharma, Cipla Inc., Rowan Bioceuticals, Glenmark Pharmaceuticals, Win-Medicare Pvt. Ltd. 등이 있습니다.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL PSORIASIS TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL PSORIASIS TREATMENT MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL PSORIASIS TREATMENT MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER'S 5 FORCES
4.2 PESTEL ANALYSIS
5 EPIDEMIOLOGY
5.1 INCIDENCE OF ALL BY GENDER
5.2 TREATMENT RATE
5.3 MORTALITY RATE
5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
5.5 PATEINT TREATMENT SUCCESS RATES
6 INDUSTRY INSIGHTS
6.1 PATENT ANALYSIS
6.2 DRUG TREATMENT RATE BY MATURED MARKETS
6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
6.4 PATIENT FLOW DIAGRAM
6.5 KEY PRICING STRATEGIES
6.6 KEY PATIENT ENROLLMENT STRATEGIES
6.7 INTERVIEWS WITH DERMATOLOGIST
6.8 OTHER KOL SNAPSHOTS
7 REGULATORY SCENARIO
7.1 FDA APPROVALS
7.2 EMA APPROVALS
8 MERGERS AND ACQUISITION
8.1 LICENSING
8.2 COMMERCIALIZATION AGREEMENTS
9 PIPELINE ANALYSIS
9.1 CLINICAL TRIALS AND PHASE ANALYSIS
9.2 DRUG THERAPY PIPELINE
9.3 PHASE III CANDIDATES
9.4 PHASE II CANDIDATES
9.5 PHASE I CANDIDATES
9.6 OTHERS (PRE-CLINICAL AND RESEARCH)
10 MARKET OVERVIEW
10.1 DRIVERS
10.2 RESTRAINS
10.3 OPPURTUNITY
10.4 CHALLENGES
11 GLOBAL PSORIASIS TREATMENT MARKET, BY DISEASE TYPE
11.1 OVERVIEW
11.2 PLAQUE PSORIASIS, BY TREATMENT
11.2.1 MEDICATION
11.2.1.1. CORTICOSTEROIDS
11.2.1.1.1. HYDROCORTISONE, BY BRAND
11.2.1.1.1.1 HYDROCORT
11.2.1.1.1.1.1. MARKET VALUE (USD MN)
A. MARKET VOLUME (IU)
B. AVERAGE SELLING PRICE (USD)
11.2.1.1.1.2 ALPHOSYL
11.2.1.1.1.2.1. MARKET VALUE (USD MN)
11.2.1.1.1.2.2. MARKET VOLUME (IU)
11.2.1.1.1.2.3. AVERAGE SELLING PRICE (USD)
11.2.1.1.1.3 AQUACORT
11.2.1.1.1.3.1. MARKET VALUE (USD MN)
11.2.1.1.1.3.2. MARKET VOLUME (IU)
11.2.1.1.1.3.3. AVERAGE SELLING PRICE (USD)
11.2.1.1.1.4 OTHERS
11.2.1.1.2. TRIAMCINOLONE, BY BRAND
11.2.1.1.2.1 KENALOG IV
11.2.1.1.2.1.1. MARKET VALUE (USD MN)
11.2.1.1.2.1.2. MARKET VOLUME (IU)
11.2.1.1.2.1.3. AVERAGE SELLING PRICE (USD)
11.2.1.1.2.2 ARISTOSPAN
11.2.1.1.2.2.1. MARKET VALUE (USD MN)
11.2.1.1.2.2.2. MARKET VOLUME (IU)
11.2.1.1.2.2.3. AVERAGE SELLING PRICE (USD)
11.2.1.1.2.3 TRIVARIS
11.2.1.1.2.3.1. MARKET VALUE (USD MN)
11.2.1.1.2.3.2. MARKET VOLUME (IU)
11.2.1.1.2.3.3. AVERAGE SELLING PRICE (USD)
11.2.1.1.2.4 OTHERS
11.2.1.1.3. CLOBETASOL, BY BRAND
11.2.1.1.3.1 TEMOVATE
11.2.1.1.3.1.1. MARKET VALUE (USD MN)
11.2.1.1.3.1.2. MARKET VOLUME (IU)
11.2.1.1.3.1.3. AVERAGE SELLING PRICE (USD)
11.2.1.1.3.2 CLOBEX
11.2.1.1.3.2.1. MARKET VALUE (USD MN)
11.2.1.1.3.2.2. MARKET VOLUME (IU)
11.2.1.1.3.2.3. AVERAGE SELLING PRICE (USD)
11.2.1.1.3.3 OLUX
11.2.1.1.3.3.1. MARKET VALUE (USD MN)
11.2.1.1.3.3.2. MARKET VOLUME (IU)
11.2.1.1.3.3.3. AVERAGE SELLING PRICE (USD)
11.2.1.1.3.4 OTHERS
11.2.1.2. CALCINEURIN INHIBITORS
11.2.1.2.1. TACROLIMUS, BY BRAND
11.2.1.2.1.1 PROGRAF
11.2.1.2.1.1.1. MARKET VALUE (USD MN)
11.2.1.2.1.1.2. MARKET VOLUME (IU)
11.2.1.2.1.1.3. AVERAGE SELLING PRICE (USD)
11.2.1.2.1.2 ENVARSUS XR
11.2.1.2.1.2.1. MARKET VALUE (USD MN)
11.2.1.2.1.2.2. MARKET VOLUME (IU)
11.2.1.2.1.2.3. AVERAGE SELLING PRICE (USD)
11.2.1.2.1.3 ASTAGRAF XL
11.2.1.2.1.3.1. MARKET VALUE (USD MN)
11.2.1.2.1.3.2. MARKET VOLUME (IU)
11.2.1.2.1.3.3. AVERAGE SELLING PRICE (USD)
11.2.1.2.1.4 OTHERS
11.2.1.2.2. PIMECROLIMUS (ELIDEL)
11.2.1.2.2.1.1. MARKET VALUE (USD MN)
11.2.1.2.2.1.2. MARKET VOLUME (IU)
11.2.1.2.2.1.3. AVERAGE SELLING PRICE (USD)
11.2.1.3. IMMUNOSUPPRESSANT
11.2.1.3.1. CYCLOSPORINE, BY BRAND NAME
11.2.1.3.1.1 SANDMMUNE
11.2.1.3.1.1.1. MARKET VALUE (USD MN)
11.2.1.3.1.1.2. MARKET VOLUME (IU)
11.2.1.3.1.1.3. AVERAGE SELLING PRICE (USD)
11.2.1.3.1.2 NEORAL
11.2.1.3.1.2.1. MARKET VALUE (USD MN)
11.2.1.3.1.2.2. MARKET VOLUME (IU)
11.2.1.3.1.2.3. AVERAGE SELLING PRICE (USD)
11.2.1.3.1.3 RESTASIS
11.2.1.3.1.3.1. MARKET VALUE (USD MN)
11.2.1.3.1.3.2. MARKET VOLUME (IU)
11.2.1.3.1.3.3. AVERAGE SELLING PRICE (USD)
11.2.1.3.1.4 OTHERS
11.2.1.3.2. METHOTREXATE, BY BRAND NAME
11.2.1.3.2.1 TREXALL
11.2.1.3.2.1.1. MARKET VALUE (USD MN)
11.2.1.3.2.1.2. MARKET VOLUME (IU)
11.2.1.3.2.1.3. AVERAGE SELLING PRICE (USD)
11.2.1.3.2.2 OTREXUP
11.2.1.3.2.2.1. MARKET VALUE (USD MN)
11.2.1.3.2.2.2. MARKET VOLUME (IU)
11.2.1.3.2.2.3. AVERAGE SELLING PRICE (USD)
11.2.1.3.2.3 RASUVO
11.2.1.3.2.3.1. MARKET VALUE (USD MN)
11.2.1.3.2.3.2. MARKET VOLUME (IU)
11.2.1.3.2.3.3. AVERAGE SELLING PRICE (USD)
11.2.1.3.2.4 OTHERS
11.2.1.3.3. BIOLOGIC DRUGS
11.2.1.3.3.1 TUMOR NECROSIS FACTOR-ALPHA (TNF-ALPHA) INHIBITORS
11.2.1.3.3.1.1. CERTOLIZUMAB PEGOL (CIMZIA)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.2.1.3.3.1.2. ETANERCEPT, BY BRAND NAME
A. ENBREL
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
B. ERELZI
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
C. OTHERS
11.2.1.3.3.1.3. ADALIMUMAB, BY BRAND
A. HUMIRA
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
B. AMGEVITA
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
C. HYRIMOZ
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
D. OTHERS
11.2.1.3.3.1.4. INFLIXIMAB, BY BRAND
A. REMICADE
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
B. RENFLEXIS
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
C. OTERS
11.2.1.3.3.1.5. GOLIMUMAB, (SIMPONI)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.2.1.3.3.1.6. OTHERS
11.2.1.3.3.2 INTERLEUKIN
11.2.1.3.3.2.1. USTEKINUMAB (STELARA)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
11.2.1.3.3.2.2. AVERAGE SELLING PRICE (USD SECUKINUMAB (COSENTYX)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.2.1.3.3.2.3. GUSELKUMAB (TREMFYA)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.2.1.3.3.2.4. OTHERS
11.2.1.3.3.3 T-CELL INHIBITORS/ ABATACEPT
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.2.1.3.4. OTHERS
11.2.2 TOPICAL THERAPY
11.2.2.1. VITAMIN D
11.2.2.1.1. CALCIPOTRIENE,BY BRAND
11.2.2.1.1.1 DOVONEX
11.2.2.1.1.1.1. MARKET VALUE (USD MN)
11.2.2.1.1.1.2. MARKET VOLUME (IU)
11.2.2.1.1.1.3. AVERAGE SELLING PRICE (USD)
11.2.2.1.1.2 SORILUX
11.2.2.1.1.2.1. MARKET VALUE (USD MN)
11.2.2.1.1.2.2. MARKET VOLUME (IU)
11.2.2.1.1.2.3. AVERAGE SELLING PRICE (USD)
11.2.2.1.1.3 OTHERS
11.2.2.1.2. CALCITRIOL (VECTICAL)
11.2.2.1.2.1 MARKET VALUE (USD MN)
11.2.2.1.2.2 MARKET VOLUME (IU)
11.2.2.1.2.3 AVERAGE SELLING PRICE (USD)
11.2.2.2. RETINOIDS (TAZAROTENE), BY BRAND
11.2.2.2.1. TAZORAC
11.2.2.2.1.1 MARKET VALUE (USD MN)
11.2.2.2.1.2 MARKET VOLUME (IU)
11.2.2.2.1.3 AVERAGE SELLING PRICE (USD)
11.2.2.2.2. AVAGE
11.2.2.2.2.1 MARKET VALUE (USD MN)
11.2.2.2.2.2 MARKET VOLUME (IU)
11.2.2.2.2.3 AVERAGE SELLING PRICE (USD)
11.2.2.2.3. OTHERS
11.2.2.3. ANTHRALIN
11.2.2.3.1. MARKET VALUE (USD MN)
11.2.2.3.2. MARKET VOLUME (IU)
11.2.2.3.3. AVERAGE SELLING PRICE (USD)
11.2.2.4. SALICYLIC ACID
11.2.2.4.1. MARKET VALUE (USD MN)
11.2.2.4.2. MARKET VOLUME (IU)
11.2.2.4.3. AVERAGE SELLING PRICE (USD)
11.2.2.5. COAL TAR
11.2.2.5.1. MARKET VALUE (USD MN)
11.2.2.5.2. MARKET VOLUME (IU)
11.2.2.5.3. AVERAGE SELLING PRICE (USD)
11.2.2.6. OTHERS
11.2.3 LIGHT THERAPY
11.2.3.1. PSORALEN PLUS ULTRAVIOLET A (PUVA)
11.2.3.2. UV B
11.2.3.2.1. BROAD BAND
11.2.3.2.2. NARROW BAND
11.2.3.3. EXCIMER LASER
11.2.4 SYMPTOMATIC MEDICINE
11.2.4.1. ALOE EXTRACT CREAM
11.2.4.1.1. MARKET VALUE (USD MN)
11.2.4.1.2. MARKET VOLUME (IU)
11.2.4.1.3. AVERAGE SELLING PRICE (USD)
11.2.4.2. FISH OIL SUPPLEMENTS
11.2.4.2.1. MARKET VALUE (USD MN)
11.2.4.2.2. MARKET VOLUME (IU)
11.2.4.2.3. AVERAGE SELLING PRICE (USD)
11.2.4.3. OREGON GRAPE
11.2.4.3.1. MARKET VALUE (USD MN)
11.2.4.3.2. MARKET VOLUME (IU)
11.2.4.3.3. AVERAGE SELLING PRICE (USD)
11.3 GUTTATE PSORIASIS
11.3.1 MEDICATION
11.3.1.1. CORTICOSTEROIDS
11.3.1.1.1. HYDROCORTISONE, BY BRAND
11.3.1.1.1.1 HYDROCORT
11.3.1.1.1.1.1. MARKET VALUE (USD MN)
11.3.1.1.1.1.2. MARKET VOLUME (IU)
11.3.1.1.1.1.3. AVERAGE SELLING PRICE (USD)
11.3.1.1.1.2 ALPHOSYL
11.3.1.1.1.2.1. MARKET VALUE (USD MN)
11.3.1.1.1.2.2. MARKET VOLUME (IU)
11.3.1.1.1.2.3. AVERAGE SELLING PRICE (USD)
11.3.1.1.1.3 AQUACORT
11.3.1.1.1.3.1. MARKET VALUE (USD MN)
11.3.1.1.1.3.2. MARKET VOLUME (IU)
11.3.1.1.1.3.3. AVERAGE SELLING PRICE (USD)
11.3.1.1.1.4 OTHERS
11.3.1.1.2. TRIAMCINOLONE, BY BRAND
11.3.1.1.2.1 KENALOG IV
11.3.1.1.2.1.1. MARKET VALUE (USD MN)
11.3.1.1.2.1.2. MARKET VOLUME (IU)
11.3.1.1.2.1.3. AVERAGE SELLING PRICE (USD)
11.3.1.1.2.2 ARISTOSPAN
11.3.1.1.2.2.1. MARKET VALUE (USD MN)
11.3.1.1.2.2.2. MARKET VOLUME (IU)
11.3.1.1.2.2.3. AVERAGE SELLING PRICE (USD)
11.3.1.1.2.3 TRIVARIS
11.3.1.1.2.3.1. MARKET VALUE (USD MN)
11.3.1.1.2.3.2. MARKET VOLUME (IU)
11.3.1.1.2.3.3. AVERAGE SELLING PRICE (USD)
11.3.1.1.2.4 OTHERS
11.3.1.1.3. CLOBETASOL, BY BRAND
11.3.1.1.3.1 TEMOVATE
11.3.1.1.3.1.1. MARKET VALUE (USD MN)
11.3.1.1.3.1.2. MARKET VOLUME (IU)
11.3.1.1.3.1.3. AVERAGE SELLING PRICE (USD)
11.3.1.1.3.2 CLOBEX
11.3.1.1.3.2.1. MARKET VALUE (USD MN)
11.3.1.1.3.2.2. MARKET VOLUME (IU)
11.3.1.1.3.2.3. AVERAGE SELLING PRICE (USD)
11.3.1.1.3.3 OLUX
11.3.1.1.3.3.1. MARKET VALUE (USD MN)
11.3.1.1.3.3.2. MARKET VOLUME (IU)
11.3.1.1.3.3.3. AVERAGE SELLING PRICE (USD)
11.3.1.1.3.4 OTHERS
11.3.1.2. CALCINEURIN INHIBITORS
11.3.1.2.1. TACROLIMUS, BY BRAND
11.3.1.2.1.1 PROGRAF
11.3.1.2.1.1.1. MARKET VALUE (USD MN)
11.3.1.2.1.1.2. MARKET VOLUME (IU)
11.3.1.2.1.1.3. AVERAGE SELLING PRICE (USD)
11.3.1.2.1.2 ENVARSUS XR
11.3.1.2.1.2.1. MARKET VALUE (USD MN)
11.3.1.2.1.2.2. MARKET VOLUME (IU)
11.3.1.2.1.2.3. AVERAGE SELLING PRICE (USD)
11.3.1.2.1.3 ASTAGRAF XL
11.3.1.2.1.3.1. MARKET VALUE (USD MN)
11.3.1.2.1.3.2. MARKET VOLUME (IU)
11.3.1.2.1.3.3. AVERAGE SELLING PRICE (USD)
11.3.1.2.1.4 OTHERS
11.3.1.2.2. PIMECROLIMUS (ELIDEL)
11.3.1.2.2.1.1. MARKET VALUE (USD MN)
11.3.1.2.2.1.2. MARKET VOLUME (IU)
11.3.1.2.2.1.3. AVERAGE SELLING PRICE (USD)
11.3.1.3. IMMUNOSUPPRESSANT
11.3.1.3.1. CYCLOSPORINE, BY BRAND NAME
11.3.1.3.1.1 SANDMMUNE
11.3.1.3.1.1.1. MARKET VALUE (USD MN)
11.3.1.3.1.1.2. MARKET VOLUME (IU)
11.3.1.3.1.1.3. AVERAGE SELLING PRICE (USD)
11.3.1.3.1.2 NEORAL
11.3.1.3.1.2.1. MARKET VALUE (USD MN)
11.3.1.3.1.2.2. MARKET VOLUME (IU)
11.3.1.3.1.2.3. AVERAGE SELLING PRICE (USD)
11.3.1.3.1.3 RESTASIS
11.3.1.3.1.3.1. MARKET VALUE (USD MN)
11.3.1.3.1.3.2. MARKET VOLUME (IU)
11.3.1.3.1.3.3. AVERAGE SELLING PRICE (USD)
11.3.1.3.1.4 OTHERS
11.3.1.3.2. METHOTREXATE, BY BRAND NAME
11.3.1.3.2.1 TREXALL
11.3.1.3.2.1.1. MARKET VALUE (USD MN)
11.3.1.3.2.1.2. MARKET VOLUME (IU)
11.3.1.3.2.1.3. AVERAGE SELLING PRICE (USD)
11.3.1.3.2.2 OTREXUP
11.3.1.3.2.2.1. MARKET VALUE (USD MN)
11.3.1.3.2.2.2. MARKET VOLUME (IU)
11.3.1.3.2.2.3. AVERAGE SELLING PRICE (USD)
11.3.1.3.2.3 RASUVO
11.3.1.3.2.3.1. MARKET VALUE (USD MN)
11.3.1.3.2.3.2. MARKET VOLUME (IU)
11.3.1.3.2.3.3. AVERAGE SELLING PRICE (USD)
11.3.1.3.2.4 OTHERS
11.3.1.3.3. BIOLOGIC DRUGS
11.3.1.3.3.1 TUMOR NECROSIS FACTOR-ALPHA (TNF-ALPHA) INHIBITORS
11.3.1.3.3.1.1. CERTOLIZUMAB PEGOL (CIMZIA)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.3.1.3.3.1.2. ETANERCEPT, BY BRAND NAME
A. ENBREL
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
B. ERELZI
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
C. OTHERS
11.3.1.3.3.1.3. ADALIMUMAB, BY BRAND
A. HUMIRA
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
B. AMGEVITA
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
C. HYRIMOZ
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
D. OTHERS
11.3.1.3.3.1.4. INFLIXIMAB, BY BRAND
A. REMICADE
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
B. RENFLEXIS
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
C. OTERS
11.3.1.3.3.1.5. GOLIMUMAB, (SIMPONI)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.3.1.3.3.1.6. OTHERS
11.3.1.3.3.2 INTERLEUKIN
11.3.1.3.3.2.1. USTEKINUMAB (STELARA)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.3.1.3.3.2.2. SECUKINUMAB (COSENTYX)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.3.1.3.3.2.3. GUSELKUMAB (TREMFYA)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.3.1.3.3.2.4. OTHERS
11.3.1.3.3.3 T-CELL INHIBITORS/ ABATACEPT
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.3.1.3.4. OTHERS
11.3.2 TOPICAL THERAPY
11.3.2.1. VITAMIN D
11.3.2.1.1. CALCIPOTRIENE,BY BRAND
11.3.2.1.1.1 DOVONEX
11.3.2.1.1.1.1. MARKET VALUE (USD MN)
11.3.2.1.1.1.2. MARKET VOLUME (IU)
11.3.2.1.1.1.3. AVERAGE SELLING PRICE (USD)
11.3.2.1.1.2 SORILUX
11.3.2.1.1.2.1. MARKET VALUE (USD MN)
11.3.2.1.1.2.2. MARKET VOLUME (IU)
11.3.2.1.1.2.3. AVERAGE SELLING PRICE (USD)
11.3.2.1.1.3 OTHERS
11.3.2.1.2. CALCITRIOL (VECTICAL)
11.3.2.1.2.1 MARKET VALUE (USD MN)
11.3.2.1.2.2 MARKET VOLUME (IU)
11.3.2.1.2.3 AVERAGE SELLING PRICE (USD)
11.3.2.2. RETINOIDS (TAZAROTENE), BY BRAND
11.3.2.2.1. TAZORAC
11.3.2.2.1.1 MARKET VALUE (USD MN)
11.3.2.2.1.2 MARKET VOLUME (IU)
11.3.2.2.1.3 AVERAGE SELLING PRICE (USD)
11.3.2.2.2. AVAGE
11.3.2.2.2.1 MARKET VALUE (USD MN)
11.3.2.2.2.2 MARKET VOLUME (IU)
11.3.2.2.2.3 AVERAGE SELLING PRICE (USD)
11.3.2.2.3. OTHERS
11.3.2.3. ANTHRALIN
11.3.2.3.1. MARKET VALUE (USD MN)
11.3.2.3.2. MARKET VOLUME (IU)
11.3.2.3.3. AVERAGE SELLING PRICE (USD)
11.3.2.4. SALICYLIC ACID
11.3.2.4.1. MARKET VALUE (USD MN)
11.3.2.4.2. MARKET VOLUME (IU)
11.3.2.4.3. AVERAGE SELLING PRICE (USD)
11.3.2.5. COAL TAR
11.3.2.5.1. MARKET VALUE (USD MN)
11.3.2.5.2. MARKET VOLUME (IU)
11.3.2.5.3. AVERAGE SELLING PRICE (USD)
11.3.2.6. OTHERS
11.3.3 LIGHT THERAPY
11.3.3.1. PSORALEN PLUS ULTRAVIOLET A (PUVA)
11.3.3.2. UV B
11.3.3.2.1. BROAD BAND
11.3.3.2.2. NARROW BAND
11.3.3.3. EXCIMER LASER
11.3.4 SYMPTOMATIC MEDICINE
11.3.4.1. ALOE EXTRACT CREAM
11.3.4.1.1. MARKET VALUE (USD MN)
11.3.4.1.2. MARKET VOLUME (IU)
11.3.4.1.3. AVERAGE SELLING PRICE (USD)
11.3.4.2. FISH OIL SUPPLEMENTS
11.3.4.2.1. MARKET VALUE (USD MN)
11.3.4.2.2. MARKET VOLUME (IU)
11.3.4.2.3. AVERAGE SELLING PRICE (USD)
11.3.4.3. OREGON GRAPE
11.3.4.3.1. MARKET VALUE (USD MN)
11.3.4.3.2. MARKET VOLUME (IU)
11.3.4.3.3. AVERAGE SELLING PRICE (USD)
11.4 INVERSE PSORIASIS
11.4.1 MEDICATION
11.4.1.1. CORTICOSTEROIDS
11.4.1.1.1. HYDROCORTISONE, BY BRAND
11.4.1.1.1.1 HYDROCORT
11.4.1.1.1.1.1. MARKET VALUE (USD MN)
11.4.1.1.1.1.2. MARKET VOLUME (IU)
11.4.1.1.1.1.3. AVERAGE SELLING PRICE (USD)
11.4.1.1.1.2 ALPHOSYL
11.4.1.1.1.2.1. MARKET VALUE (USD MN)
11.4.1.1.1.2.2. MARKET VOLUME (IU)
11.4.1.1.1.2.3. AVERAGE SELLING PRICE (USD)
11.4.1.1.1.3 AQUACORT
11.4.1.1.1.3.1. MARKET VALUE (USD MN)
11.4.1.1.1.3.2. MARKET VOLUME (IU)
11.4.1.1.1.3.3. AVERAGE SELLING PRICE (USD)
11.4.1.1.1.4 OTHERS
11.4.1.1.2. TRIAMCINOLONE, BY BRAND
11.4.1.1.2.1 KENALOG IV
11.4.1.1.2.1.1. MARKET VALUE (USD MN)
11.4.1.1.2.1.2. MARKET VOLUME (IU)
11.4.1.1.2.1.3. AVERAGE SELLING PRICE (USD)
11.4.1.1.2.2 ARISTOSPAN
11.4.1.1.2.2.1. MARKET VALUE (USD MN)
11.4.1.1.2.2.2. MARKET VOLUME (IU)
11.4.1.1.2.2.3. AVERAGE SELLING PRICE (USD)
11.4.1.1.2.3 TRIVARIS
11.4.1.1.2.3.1. MARKET VALUE (USD MN)
11.4.1.1.2.3.2. MARKET VOLUME (IU)
11.4.1.1.2.3.3. AVERAGE SELLING PRICE (USD)
11.4.1.1.2.4 OTHERS
11.4.1.1.3. CLOBETASOL, BY BRAND
11.4.1.1.3.1 TEMOVATE
11.4.1.1.3.1.1. MARKET VALUE (USD MN)
11.4.1.1.3.1.2. MARKET VOLUME (IU)
11.4.1.1.3.1.3. AVERAGE SELLING PRICE (USD)
11.4.1.1.3.2 CLOBEX
11.4.1.1.3.2.1. MARKET VALUE (USD MN)
11.4.1.1.3.2.2. MARKET VOLUME (IU)
11.4.1.1.3.2.3. AVERAGE SELLING PRICE (USD)
11.4.1.1.3.3 OLUX
11.4.1.1.3.3.1. MARKET VALUE (USD MN)
11.4.1.1.3.3.2. MARKET VOLUME (IU)
11.4.1.1.3.3.3. AVERAGE SELLING PRICE (USD)
11.4.1.1.3.4 OTHERS
11.4.1.2. CALCINEURIN INHIBITORS
11.4.1.2.1. TACROLIMUS, BY BRAND
11.4.1.2.1.1 PROGRAF
11.4.1.2.1.1.1. MARKET VALUE (USD MN)
11.4.1.2.1.1.2. MARKET VOLUME (IU)
11.4.1.2.1.1.3. AVERAGE SELLING PRICE (USD)
11.4.1.2.1.2 ENVARSUS XR
11.4.1.2.1.2.1. MARKET VALUE (USD MN)
11.4.1.2.1.2.2. MARKET VOLUME (IU)
11.4.1.2.1.2.3. AVERAGE SELLING PRICE (USD)
11.4.1.2.1.3 ASTAGRAF XL
11.4.1.2.1.3.1. MARKET VALUE (USD MN)
11.4.1.2.1.3.2. MARKET VOLUME (IU)
11.4.1.2.1.3.3. AVERAGE SELLING PRICE (USD)
11.4.1.2.1.4 OTHERS
11.4.1.2.2. PIMECROLIMUS (ELIDEL)
11.4.1.2.2.1.1. MARKET VALUE (USD MN)
11.4.1.2.2.1.2. MARKET VOLUME (IU)
11.4.1.2.2.1.3. AVERAGE SELLING PRICE (USD)
11.4.1.3. IMMUNOSUPPRESSANT
11.4.1.3.1. CYCLOSPORINE, BY BRAND NAME
11.4.1.3.1.1 SANDMMUNE
11.4.1.3.1.1.1. MARKET VALUE (USD MN)
11.4.1.3.1.1.2. MARKET VOLUME (IU)
11.4.1.3.1.1.3. AVERAGE SELLING PRICE (USD)
11.4.1.3.1.2 NEORAL
11.4.1.3.1.2.1. MARKET VALUE (USD MN)
11.4.1.3.1.2.2. MARKET VOLUME (IU)
11.4.1.3.1.2.3. AVERAGE SELLING PRICE (USD)
11.4.1.3.1.3 RESTASIS
11.4.1.3.1.3.1. MARKET VALUE (USD MN)
11.4.1.3.1.3.2. MARKET VOLUME (IU)
11.4.1.3.1.3.3. AVERAGE SELLING PRICE (USD)
11.4.1.3.1.4 OTHERS
11.4.1.3.2. METHOTREXATE, BY BRAND NAME
11.4.1.3.2.1 TREXALL
11.4.1.3.2.1.1. MARKET VALUE (USD MN)
11.4.1.3.2.1.2. MARKET VOLUME (IU)
11.4.1.3.2.1.3. AVERAGE SELLING PRICE (USD)
11.4.1.3.2.2 OTREXUP
11.4.1.3.2.2.1. MARKET VALUE (USD MN)
11.4.1.3.2.2.2. MARKET VOLUME (IU)
11.4.1.3.2.2.3. AVERAGE SELLING PRICE (USD)
11.4.1.3.2.3 RASUVO
11.4.1.3.2.3.1. MARKET VALUE (USD MN)
11.4.1.3.2.3.2. MARKET VOLUME (IU)
11.4.1.3.2.3.3. AVERAGE SELLING PRICE (USD)
11.4.1.3.2.4 OTHERS
11.4.1.3.3. BIOLOGIC DRUGS
11.4.1.3.3.1 TUMOR NECROSIS FACTOR-ALPHA (TNF-ALPHA) INHIBITORS
11.4.1.3.3.1.1. CERTOLIZUMAB PEGOL (CIMZIA)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.4.1.3.3.1.2. ETANERCEPT, BY BRAND NAME
A. ENBREL
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
B. ERELZI
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
C. OTHERS
11.4.1.3.3.1.3. ADALIMUMAB, BY BRAND
A. HUMIRA
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
B. AMGEVITA
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
C. HYRIMOZ
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
D. OTHERS
11.4.1.3.3.1.4. INFLIXIMAB, BY BRAND
A. REMICADE
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
B. RENFLEXIS
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
C. OTERS
11.4.1.3.3.1.5. GOLIMUMAB, (SIMPONI)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.4.1.3.3.1.6. OTHERS
11.4.1.3.3.2 INTERLEUKIN
11.4.1.3.3.2.1. USTEKINUMAB (STELARA)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.4.1.3.3.2.2. SECUKINUMAB (COSENTYX)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.4.1.3.3.2.3. GUSELKUMAB (TREMFYA)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.4.1.3.3.2.4. OTHERS
11.4.1.3.3.3 T-CELL INHIBITORS/ ABATACEPT
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.4.1.3.4. OTHERS
11.4.2 TOPICAL THERAPY
11.4.2.1. VITAMIN D
11.4.2.1.1. CALCIPOTRIENE,BY BRAND
11.4.2.1.1.1 DOVONEX
11.4.2.1.1.1.1. MARKET VALUE (USD MN)
11.4.2.1.1.1.2. MARKET VOLUME (IU)
11.4.2.1.1.1.3. AVERAGE SELLING PRICE (USD)
11.4.2.1.1.2 SORILUX
11.4.2.1.1.2.1. MARKET VALUE (USD MN)
11.4.2.1.1.2.2. MARKET VOLUME (IU)
11.4.2.1.1.2.3. AVERAGE SELLING PRICE (USD)
11.4.2.1.1.3 OTHERS
11.4.2.1.2. CALCITRIOL (VECTICAL)
11.4.2.1.2.1 MARKET VALUE (USD MN)
11.4.2.1.2.2 MARKET VOLUME (IU)
11.4.2.1.2.3 AVERAGE SELLING PRICE (USD)
11.4.2.2. RETINOIDS (TAZAROTENE), BY BRAND
11.4.2.2.1. TAZORAC
11.4.2.2.1.1 MARKET VALUE (USD MN)
11.4.2.2.1.2 MARKET VOLUME (IU)
11.4.2.2.1.3 AVERAGE SELLING PRICE (USD)
11.4.2.2.2. AVAGE
11.4.2.2.2.1 MARKET VALUE (USD MN)
11.4.2.2.2.2 MARKET VOLUME (IU)
11.4.2.2.2.3 AVERAGE SELLING PRICE (USD)
11.4.2.2.3. OTHERS
11.4.2.3. ANTHRALIN
11.4.2.3.1. MARKET VALUE (USD MN)
11.4.2.3.2. MARKET VOLUME (IU)
11.4.2.3.3. AVERAGE SELLING PRICE (USD)
11.4.2.4. SALICYLIC ACID
11.4.2.4.1. MARKET VALUE (USD MN)
11.4.2.4.2. MARKET VOLUME (IU)
11.4.2.4.3. AVERAGE SELLING PRICE (USD)
11.4.2.5. COAL TAR
11.4.2.5.1. MARKET VALUE (USD MN)
11.4.2.5.2. MARKET VOLUME (IU)
11.4.2.5.3. AVERAGE SELLING PRICE (USD)
11.4.2.6. OTHERS
11.4.3 LIGHT THERAPY
11.4.3.1. PSORALEN PLUS ULTRAVIOLET A (PUVA)
11.4.3.2. UV B
11.4.3.2.1. BROAD BAND
11.4.3.2.2. NARROW BAND
11.4.3.3. EXCIMER LASER
11.4.4 SYMPTOMATIC MEDICINE
11.4.4.1. ALOE EXTRACT CREAM
11.4.4.1.1. MARKET VALUE (USD MN)
11.4.4.1.2. MARKET VOLUME (IU)
11.4.4.1.3. AVERAGE SELLING PRICE (USD)
11.4.4.2. FISH OIL SUPPLEMENTS
11.4.4.2.1. MARKET VALUE (USD MN)
11.4.4.2.2. MARKET VOLUME (IU)
11.4.4.2.3. AVERAGE SELLING PRICE (USD)
11.4.4.3. OREGON GRAPE
11.4.4.3.1. MARKET VALUE (USD MN)
11.4.4.3.2. MARKET VOLUME (IU)
11.4.4.3.3. AVERAGE SELLING PRICE (USD)
11.5 PUSTULAR PSORIASIS
11.5.1 MEDICATION
11.5.1.1. CORTICOSTEROIDS
11.5.1.1.1. HYDROCORTISONE, BY BRAND
11.5.1.1.1.1 HYDROCORT
11.5.1.1.1.1.1. MARKET VALUE (USD MN)
11.5.1.1.1.1.2. MARKET VOLUME (IU)
11.5.1.1.1.1.3. AVERAGE SELLING PRICE (USD)
11.5.1.1.1.2 ALPHOSYL
11.5.1.1.1.2.1. MARKET VALUE (USD MN)
11.5.1.1.1.2.2. MARKET VOLUME (IU)
11.5.1.1.1.2.3. AVERAGE SELLING PRICE (USD)
11.5.1.1.1.3 AQUACORT
11.5.1.1.1.3.1. MARKET VALUE (USD MN)
11.5.1.1.1.3.2. MARKET VOLUME (IU)
11.5.1.1.1.3.3. AVERAGE SELLING PRICE (USD)
11.5.1.1.1.4 OTHERS
11.5.1.1.2. TRIAMCINOLONE, BY BRAND
11.5.1.1.2.1 KENALOG IV
11.5.1.1.2.1.1. MARKET VALUE (USD MN)
11.5.1.1.2.1.2. MARKET VOLUME (IU)
11.5.1.1.2.1.3. AVERAGE SELLING PRICE (USD)
11.5.1.1.2.2 ARISTOSPAN
11.5.1.1.2.2.1. MARKET VALUE (USD MN)
11.5.1.1.2.2.2. MARKET VOLUME (IU)
11.5.1.1.2.2.3. AVERAGE SELLING PRICE (USD)
11.5.1.1.2.3 TRIVARIS
11.5.1.1.2.3.1. MARKET VALUE (USD MN)
11.5.1.1.2.3.2. MARKET VOLUME (IU)
11.5.1.1.2.3.3. AVERAGE SELLING PRICE (USD)
11.5.1.1.2.4 OTHERS
11.5.1.1.3. CLOBETASOL, BY BRAND
11.5.1.1.3.1 TEMOVATE
11.5.1.1.3.1.1. MARKET VALUE (USD MN)
11.5.1.1.3.1.2. MARKET VOLUME (IU)
11.5.1.1.3.1.3. AVERAGE SELLING PRICE (USD)
11.5.1.1.3.2 CLOBEX
11.5.1.1.3.2.1. MARKET VALUE (USD MN)
11.5.1.1.3.2.2. MARKET VOLUME (IU)
11.5.1.1.3.2.3. AVERAGE SELLING PRICE (USD)
11.5.1.1.3.3 OLUX
11.5.1.1.3.3.1. MARKET VALUE (USD MN)
11.5.1.1.3.3.2. MARKET VOLUME (IU)
11.5.1.1.3.3.3. AVERAGE SELLING PRICE (USD)
11.5.1.1.3.4 OTHERS
11.5.1.2. CALCINEURIN INHIBITORS
11.5.1.2.1. TACROLIMUS, BY BRAND
11.5.1.2.1.1 PROGRAF
11.5.1.2.1.1.1. MARKET VALUE (USD MN)
11.5.1.2.1.1.2. MARKET VOLUME (IU)
11.5.1.2.1.1.3. AVERAGE SELLING PRICE (USD)
11.5.1.2.1.2 ENVARSUS XR
11.5.1.2.1.2.1. MARKET VALUE (USD MN)
11.5.1.2.1.2.2. MARKET VOLUME (IU)
11.5.1.2.1.2.3. AVERAGE SELLING PRICE (USD)
11.5.1.2.1.3 ASTAGRAF XL
11.5.1.2.1.3.1. MARKET VALUE (USD MN)
11.5.1.2.1.3.2. MARKET VOLUME (IU)
11.5.1.2.1.3.3. AVERAGE SELLING PRICE (USD)
11.5.1.2.1.4 OTHERS
11.5.1.2.2. PIMECROLIMUS (ELIDEL)
11.5.1.2.2.1.1. MARKET VALUE (USD MN)
11.5.1.2.2.1.2. MARKET VOLUME (IU)
11.5.1.2.2.1.3. AVERAGE SELLING PRICE (USD)
11.5.1.3. IMMUNOSUPPRESSANT
11.5.1.3.1. CYCLOSPORINE, BY BRAND NAME
11.5.1.3.1.1 SANDMMUNE
11.5.1.3.1.1.1. MARKET VALUE (USD MN)
11.5.1.3.1.1.2. MARKET VOLUME (IU)
11.5.1.3.1.1.3. AVERAGE SELLING PRICE (USD)
11.5.1.3.1.2 NEORAL
11.5.1.3.1.2.1. MARKET VALUE (USD MN)
11.5.1.3.1.2.2. MARKET VOLUME (IU)
11.5.1.3.1.2.3. AVERAGE SELLING PRICE (USD)
11.5.1.3.1.3 RESTASIS
11.5.1.3.1.3.1. MARKET VALUE (USD MN)
11.5.1.3.1.3.2. MARKET VOLUME (IU)
11.5.1.3.1.3.3. AVERAGE SELLING PRICE (USD)
11.5.1.3.1.4 OTHERS
11.5.1.3.2. METHOTREXATE, BY BRAND NAME
11.5.1.3.2.1 TREXALL
11.5.1.3.2.1.1. MARKET VALUE (USD MN)
11.5.1.3.2.1.2. MARKET VOLUME (IU)
11.5.1.3.2.1.3. AVERAGE SELLING PRICE (USD)
11.5.1.3.2.2 OTREXUP
11.5.1.3.2.2.1. MARKET VALUE (USD MN)
11.5.1.3.2.2.2. MARKET VOLUME (IU)
11.5.1.3.2.2.3. AVERAGE SELLING PRICE (USD)
11.5.1.3.2.3 RASUVO
11.5.1.3.2.3.1. MARKET VALUE (USD MN)
11.5.1.3.2.3.2. MARKET VOLUME (IU)
11.5.1.3.2.3.3. AVERAGE SELLING PRICE (USD)
11.5.1.3.2.4 OTHERS
11.5.1.3.3. BIOLOGIC DRUGS
11.5.1.3.3.1 TUMOR NECROSIS FACTOR-ALPHA (TNF-ALPHA) INHIBITORS
11.5.1.3.3.1.1. CERTOLIZUMAB PEGOL (CIMZIA)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.5.1.3.3.1.2. ETANERCEPT, BY BRAND NAME
A. ENBREL
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
B. ERELZI
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
C. OTHERS
11.5.1.3.3.1.3. ADALIMUMAB, BY BRAND
A. HUMIRA
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
B. AMGEVITA
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
C. HYRIMOZ
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
D. OTHERS
11.5.1.3.3.1.4. INFLIXIMAB, BY BRAND
A. REMICADE
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
B. RENFLEXIS
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
C. OTERS
11.5.1.3.3.1.5. GOLIMUMAB, (SIMPONI)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.5.1.3.3.1.6. OTHERS
11.5.1.3.3.2 INTERLEUKIN
11.5.1.3.3.2.1. USTEKINUMAB (STELARA)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.5.1.3.3.2.2. SECUKINUMAB (COSENTYX)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.5.1.3.3.2.3. GUSELKUMAB (TREMFYA)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.5.1.3.3.2.4. OTHERS
11.5.1.3.3.3 T-CELL INHIBITORS/ ABATACEPT
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.5.1.3.4. OTHERS
11.5.2 TOPICAL THERAPY
11.5.2.1. VITAMIN D
11.5.2.1.1. CALCIPOTRIENE,BY BRAND
11.5.2.1.1.1 DOVONEX
11.5.2.1.1.1.1. MARKET VALUE (USD MN)
11.5.2.1.1.1.2. MARKET VOLUME (IU)
11.5.2.1.1.1.3. AVERAGE SELLING PRICE (USD)
11.5.2.1.1.2 SORILUX
11.5.2.1.1.2.1. MARKET VALUE (USD MN)
11.5.2.1.1.2.2. MARKET VOLUME (IU)
11.5.2.1.1.2.3. AVERAGE SELLING PRICE (USD)
11.5.2.1.1.3 OTHERS
11.5.2.1.2. CALCITRIOL (VECTICAL)
11.5.2.1.2.1 MARKET VALUE (USD MN)
11.5.2.1.2.2 MARKET VOLUME (IU)
11.5.2.1.2.3 AVERAGE SELLING PRICE (USD)
11.5.2.2. RETINOIDS (TAZAROTENE), BY BRAND
11.5.2.2.1. TAZORAC
11.5.2.2.1.1 MARKET VALUE (USD MN)
11.5.2.2.1.2 MARKET VOLUME (IU)
11.5.2.2.1.3 AVERAGE SELLING PRICE (USD)
11.5.2.2.2. AVAGE
11.5.2.2.2.1 MARKET VALUE (USD MN)
11.5.2.2.2.2 MARKET VOLUME (IU)
11.5.2.2.2.3 AVERAGE SELLING PRICE (USD)
11.5.2.2.3. OTHERS
11.5.2.3. ANTHRALIN
11.5.2.3.1. MARKET VALUE (USD MN)
11.5.2.3.2. MARKET VOLUME (IU)
11.5.2.3.3. AVERAGE SELLING PRICE (USD)
11.5.2.4. SALICYLIC ACID
11.5.2.4.1. MARKET VALUE (USD MN)
11.5.2.4.2. MARKET VOLUME (IU)
11.5.2.4.3. AVERAGE SELLING PRICE (USD)
11.5.2.5. COAL TAR
11.5.2.5.1. MARKET VALUE (USD MN)
11.5.2.5.2. MARKET VOLUME (IU)
11.5.2.5.3. AVERAGE SELLING PRICE (USD)
11.5.2.6. OTHERS
11.5.3 LIGHT THERAPY
11.5.3.1. PSORALEN PLUS ULTRAVIOLET A (PUVA)
11.5.3.2. UV B
11.5.3.2.1. BROAD BAND
11.5.3.2.2. NARROW BAND
11.5.3.3. EXCIMER LASER
11.5.4 SYMPTOMATIC MEDICINE
11.5.4.1. ALOE EXTRACT CREAM
11.5.4.1.1. MARKET VALUE (USD MN)
11.5.4.1.2. MARKET VOLUME (IU)
11.5.4.1.3. AVERAGE SELLING PRICE (USD)
11.5.4.2. FISH OIL SUPPLEMENTS
11.5.4.2.1. MARKET VALUE (USD MN)
11.5.4.2.2. MARKET VOLUME (IU)
11.5.4.2.3. AVERAGE SELLING PRICE (USD)
11.5.4.3. OREGON GRAPE
11.5.4.3.1. MARKET VALUE (USD MN)
11.5.4.3.2. MARKET VOLUME (IU)
11.5.4.3.3. AVERAGE SELLING PRICE (USD)
11.6 ERYTHRODERMIC PSORIASIS
11.6.1 MEDICATION
11.6.1.1. CORTICOSTEROIDS
11.6.1.1.1. HYDROCORTISONE, BY BRAND
11.6.1.1.1.1 HYDROCORT
11.6.1.1.1.1.1. MARKET VALUE (USD MN)
11.6.1.1.1.1.2. MARKET VOLUME (IU)
11.6.1.1.1.1.3. AVERAGE SELLING PRICE (USD)
11.6.1.1.1.2 ALPHOSYL
11.6.1.1.1.2.1. MARKET VALUE (USD MN)
11.6.1.1.1.2.2. MARKET VOLUME (IU)
11.6.1.1.1.2.3. AVERAGE SELLING PRICE (USD)
11.6.1.1.1.3 AQUACORT
11.6.1.1.1.3.1. MARKET VALUE (USD MN)
11.6.1.1.1.3.2. MARKET VOLUME (IU)
11.6.1.1.1.3.3. AVERAGE SELLING PRICE (USD)
11.6.1.1.1.4 OTHERS
11.6.1.1.2. TRIAMCINOLONE, BY BRAND
11.6.1.1.2.1 KENALOG IV
11.6.1.1.2.1.1. MARKET VALUE (USD MN)
11.6.1.1.2.1.2. MARKET VOLUME (IU)
11.6.1.1.2.1.3. AVERAGE SELLING PRICE (USD)
11.6.1.1.2.2 ARISTOSPAN
11.6.1.1.2.2.1. MARKET VALUE (USD MN)
11.6.1.1.2.2.2. MARKET VOLUME (IU)
11.6.1.1.2.2.3. AVERAGE SELLING PRICE (USD)
11.6.1.1.2.3 TRIVARIS
11.6.1.1.2.3.1. MARKET VALUE (USD MN)
11.6.1.1.2.3.2. MARKET VOLUME (IU)
11.6.1.1.2.3.3. AVERAGE SELLING PRICE (USD)
11.6.1.1.2.4 OTHERS
11.6.1.1.3. CLOBETASOL, BY BRAND
11.6.1.1.3.1 TEMOVATE
11.6.1.1.3.1.1. MARKET VALUE (USD MN)
11.6.1.1.3.1.2. MARKET VOLUME (IU)
11.6.1.1.3.1.3. AVERAGE SELLING PRICE (USD)
11.6.1.1.3.2 CLOBEX
11.6.1.1.3.2.1. MARKET VALUE (USD MN)
11.6.1.1.3.2.2. MARKET VOLUME (IU)
11.6.1.1.3.2.3. AVERAGE SELLING PRICE (USD)
11.6.1.1.3.3 OLUX
11.6.1.1.3.3.1. MARKET VALUE (USD MN)
11.6.1.1.3.3.2. MARKET VOLUME (IU)
11.6.1.1.3.3.3. AVERAGE SELLING PRICE (USD)
11.6.1.1.3.4 OTHERS
11.6.1.2. CALCINEURIN INHIBITORS
11.6.1.2.1. TACROLIMUS, BY BRAND
11.6.1.2.1.1 PROGRAF
11.6.1.2.1.1.1. MARKET VALUE (USD MN)
11.6.1.2.1.1.2. MARKET VOLUME (IU)
11.6.1.2.1.1.3. AVERAGE SELLING PRICE (USD)
11.6.1.2.1.2 ENVARSUS XR
11.6.1.2.1.2.1. MARKET VALUE (USD MN)
11.6.1.2.1.2.2. MARKET VOLUME (IU)
11.6.1.2.1.2.3. AVERAGE SELLING PRICE (USD)
11.6.1.2.1.3 ASTAGRAF XL
11.6.1.2.1.3.1. MARKET VALUE (USD MN)
11.6.1.2.1.3.2. MARKET VOLUME (IU)
11.6.1.2.1.3.3. AVERAGE SELLING PRICE (USD)
11.6.1.2.1.4 OTHERS
11.6.1.2.2. PIMECROLIMUS (ELIDEL)
11.6.1.2.2.1.1. MARKET VALUE (USD MN)
11.6.1.2.2.1.2. MARKET VOLUME (IU)
11.6.1.2.2.1.3. AVERAGE SELLING PRICE (USD)
11.6.1.3. IMMUNOSUPPRESSANT
11.6.1.3.1. CYCLOSPORINE, BY BRAND NAME
11.6.1.3.1.1 SANDMMUNE
11.6.1.3.1.1.1. MARKET VALUE (USD MN)
11.6.1.3.1.1.2. MARKET VOLUME (IU)
11.6.1.3.1.1.3. AVERAGE SELLING PRICE (USD)
11.6.1.3.1.2 NEORAL
11.6.1.3.1.2.1. MARKET VALUE (USD MN)
11.6.1.3.1.2.2. MARKET VOLUME (IU)
11.6.1.3.1.2.3. AVERAGE SELLING PRICE (USD)
11.6.1.3.1.3 RESTASIS
11.6.1.3.1.3.1. MARKET VALUE (USD MN)
11.6.1.3.1.3.2. MARKET VOLUME (IU)
11.6.1.3.1.3.3. AVERAGE SELLING PRICE (USD)
11.6.1.3.1.4 OTHERS
11.6.1.3.2. METHOTREXATE, BY BRAND NAME
11.6.1.3.2.1 TREXALL
11.6.1.3.2.1.1. MARKET VALUE (USD MN)
11.6.1.3.2.1.2. MARKET VOLUME (IU)
11.6.1.3.2.1.3. AVERAGE SELLING PRICE (USD)
11.6.1.3.2.2 OTREXUP
11.6.1.3.2.2.1. MARKET VALUE (USD MN)
11.6.1.3.2.2.2. MARKET VOLUME (IU)
11.6.1.3.2.2.3. AVERAGE SELLING PRICE (USD)
11.6.1.3.2.3 RASUVO
11.6.1.3.2.3.1. MARKET VALUE (USD MN)
11.6.1.3.2.3.2. MARKET VOLUME (IU)
11.6.1.3.2.3.3. AVERAGE SELLING PRICE (USD)
11.6.1.3.2.4 OTHERS
11.6.1.3.3. BIOLOGIC DRUGS
11.6.1.3.3.1 TUMOR NECROSIS FACTOR-ALPHA (TNF-ALPHA) INHIBITORS
11.6.1.3.3.1.1. CERTOLIZUMAB PEGOL (CIMZIA)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.6.1.3.3.1.2. ETANERCEPT, BY BRAND NAME
A. ENBREL
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
B. ERELZI
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
C. OTHERS
11.6.1.3.3.1.3. ADALIMUMAB, BY BRAND
A. HUMIRA
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
B. AMGEVITA
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
C. HYRIMOZ
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
D. OTHERS
11.6.1.3.3.1.4. INFLIXIMAB, BY BRAND
A. REMICADE
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
B. RENFLEXIS
I. MARKET VALUE (USD MN)
II. MARKET VOLUME (IU)
III. AVERAGE SELLING PRICE (USD)
C. OTERS
11.6.1.3.3.1.5. GOLIMUMAB, (SIMPONI)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.6.1.3.3.1.6. OTHERS
11.6.1.3.3.2 INTERLEUKIN
11.6.1.3.3.2.1. USTEKINUMAB (STELARA)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.6.1.3.3.2.2. SECUKINUMAB (COSENTYX)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.6.1.3.3.2.3. GUSELKUMAB (TREMFYA)
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.6.1.3.3.2.4. OTHERS
11.6.1.3.3.3 T-CELL INHIBITORS/ ABATACEPT
A. MARKET VALUE (USD MN)
B. MARKET VOLUME (IU)
C. AVERAGE SELLING PRICE (USD)
11.6.1.3.4. OTHERS
11.6.2 TOPICAL THERAPY
11.6.2.1. VITAMIN D
11.6.2.1.1. CALCIPOTRIENE,BY BRAND
11.6.2.1.1.1 DOVONEX
11.6.2.1.1.1.1. MARKET VALUE (USD MN)
11.6.2.1.1.1.2. MARKET VOLUME (IU)
11.6.2.1.1.1.3. AVERAGE SELLING PRICE (USD)
11.6.2.1.1.2 SORILUX
11.6.2.1.1.2.1. MARKET VALUE (USD MN)
11.6.2.1.1.2.2. MARKET VOLUME (IU)
11.6.2.1.1.2.3. AVERAGE SELLING PRICE (USD)
11.6.2.1.1.3 OTHERS
11.6.2.1.2. CALCITRIOL (VECTICAL)
11.6.2.1.2.1 MARKET VALUE (USD MN)
11.6.2.1.2.2 MARKET VOLUME (IU)
11.6.2.1.2.3 AVERAGE SELLING PRICE (USD)
11.6.2.2. RETINOIDS (TAZAROTENE), BY BRAND
11.6.2.2.1. TAZORAC
11.6.2.2.1.1 MARKET VALUE (USD MN)
11.6.2.2.1.2 MARKET VOLUME (IU)
11.6.2.2.1.3 AVERAGE SELLING PRICE (USD)
11.6.2.2.2. AVAGE
11.6.2.2.2.1 MARKET VALUE (USD MN)
11.6.2.2.2.2 MARKET VOLUME (IU)
11.6.2.2.2.3 AVERAGE SELLING PRICE (USD)
11.6.2.2.3. OTHERS
11.6.2.3. ANTHRALIN
11.6.2.3.1. MARKET VALUE (USD MN)
11.6.2.3.2. MARKET VOLUME (IU)
11.6.2.3.3. AVERAGE SELLING PRICE (USD)
11.6.2.4. SALICYLIC ACID
11.6.2.4.1. MARKET VALUE (USD MN)
11.6.2.4.2. MARKET VOLUME (IU)
11.6.2.4.3. AVERAGE SELLING PRICE (USD)
11.6.2.5. COAL TAR
11.6.2.5.1. MARKET VALUE (USD MN)
11.6.2.5.2. MARKET VOLUME (IU)
11.6.2.5.3. AVERAGE SELLING PRICE (USD)
11.6.2.6. OTHERS
11.6.3 LIGHT THERAPY
11.6.3.1. PSORALEN PLUS ULTRAVIOLET A (PUVA)
11.6.3.2. UV B
11.6.3.2.1. BROAD BAND
11.6.3.2.2. NARROW BAND
11.6.3.3. EXCIMER LASER
11.6.4 SYMPTOMATIC MEDICINE
11.6.4.1. ALOE EXTRACT CREAM
11.6.4.1.1. MARKET VALUE (USD MN)
11.6.4.1.2. MARKET VOLUME (IU)
11.6.4.1.3. AVERAGE SELLING PRICE (USD)
11.6.4.2. FISH OIL SUPPLEMENTS
11.6.4.2.1. MARKET VALUE (USD MN)
11.6.4.2.2. MARKET VOLUME (IU)
11.6.4.2.3. AVERAGE SELLING PRICE (USD)
11.6.4.3. OREGON GRAPE
11.6.4.3.1. MARKET VALUE (USD MN)
11.6.4.3.2. MARKET VOLUME (IU)
11.6.4.3.3. AVERAGE SELLING PRICE (USD)
12 GLOBAL PSORIASIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
12.1 OVERVIEW
12.2 ORAL
12.2.1 TABLETS
12.2.2 PILLS
12.2.3 OTHERS
12.3 PARENTERAL
12.3.1 INTRAVENOUS
12.3.2 SUBCUTANEOUS
12.3.3 OTHERS
12.4 TOPICAL
12.4.1 GEL
12.4.2 CREAM
12.4.3 FOAM
12.4.4 OINTMENTS
12.4.5 SPRAY
12.4.6 SHAMPOO
12.4.7 LOTION
12.4.8 OTHERS
13 GLOBAL PSORIASIS TREATMENT MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITAL
13.3 CLINICS
13.4 HOME HEALTHCARE
13.5 THERAPY CENTERS
13.6 OTHERS
14 GLOBAL PSORIASIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 DIRECT TENDER
14.3 HOSPITAL PHARMACY
14.4 RETAIL PHARMACY
14.5 ONLINE PHARMACY
14.6 OTHERS
15 GLOBAL PSORIASIS TREATMENT MARKET, COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: GLOBAL
15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
15.3 COMPANY SHARE ANALYSIS: EUROPE
15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
15.5 MERGERS & ACQUISITIONS
15.6 NEW PRODUCT DEVELOPMENT & APPROVALS
15.7 EXPANSIONS
15.8 REGULATORY CHANGES
15.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
16 GLOBAL PSORIASIS TREATMENT MARKET, BY GEOGRAPHY
16.1 GLOBAL PSORIASIS TREATMENT MARKET (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
16.2 NORTH AMERICA
16.2.1 U.S.
16.2.1.1. U.S. PSORIASIS TREATMENT MARKET, BY TYPE
16.2.1.2. U.S. PSORIASIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
16.2.1.3. U.S. PSORIASIS TREATMENT MARKET, BY END USER
16.2.1.4. U.S. PSORIASIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
16.3 CANADA
16.3.1 MEXICO
16.3.2 DOMINICAN REPUBLIC
16.3.3 JAMAICA
16.3.4 PANAMA
16.4 EUROPE
16.4.1 GERMANY
16.4.2 FRANCE
16.4.3 U.K.
16.4.4 HUNGARY
16.4.5 LITHUANIA
16.4.6 AUSTRIA
16.4.7 IRELAND
16.4.8 NORWAY
16.4.9 POLAND
16.4.10 ITALY
16.4.11 SPAIN
16.4.12 RUSSIA
16.4.13 TURKEY
16.4.14 NETHERLANDS
16.4.15 SWITZERLAND
16.4.16 REST OF EUROPE
16.5 ASIA-PACIFIC
16.5.1 JAPAN
16.5.2 CHINA
16.5.3 TAIWAN
16.5.4 SOUTH KOREA
16.5.5 INDIA
16.5.6 AUSTRALIA
16.5.7 SINGAPORE
16.5.8 THAILAND
16.5.9 MALAYSIA
16.5.10 INDONESIA
16.5.11 PHILIPPINES
16.5.12 VIETNAM
16.5.13 REST OF ASIA-PACIFIC
16.6 SOUTH AMERICA
16.6.1 BRAZIL
16.6.2 ECUADOR
16.6.3 CHILE
16.6.4 COLOMBIA
16.6.5 VENEZUELA
16.6.6 ARGENTINA
16.6.7 PERU
16.6.8 CURAÇAO
16.6.9 PARAGUAY
16.6.10 URUGUAY
16.6.11 TRINIDAD AND TOBAGO
16.6.12 REST OF SOUTH AMERICA
16.7 MIDDLE EAST AND AFRICA
16.7.1 SOUTH AFRICA
16.7.2 SAUDI ARABIA
16.7.3 UAE
16.7.4 EGYPT
16.7.5 KUWAIT
16.7.6 ISRAEL
16.7.7 BOLIVIA
16.7.8 REST OF MIDDLE EAST AND AFRICA
16.7.9 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
17 GLOBAL PSORIASIS TREATMENT MARKET, SWOT AND DBMR ANALYSIS
18 GLOBAL PSORIASIS TREATMENT MARKET, COMPANY PROFILE
18.1 PERRIGO COMPANY PLC
18.1.1 COMPANY OVERVIEW
18.1.2 REVENUE ANALYSIS
18.1.3 GEOGRAPHIC PRESENCE
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENTS
18.2 SANOFI
18.2.1 COMPANY OVERVIEW
18.2.2 REVENUE ANALYSIS
18.2.3 GEOGRAPHIC PRESENCE
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENTS
18.3 GLAXOSMITHKLINE
18.3.1 COMPANY OVERVIEW
18.3.2 REVENUE ANALYSIS
18.3.3 GEOGRAPHIC PRESENCE
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENTS
18.4 MERCK & CO, INC
18.4.1 COMPANY OVERVIEW
18.4.2 REVENUE ANALYSIS
18.4.3 GEOGRAPHIC PRESENCE
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENTS
18.5 F-HOFFMANN LA ROCHE
18.5.1 COMPANY OVERVIEW
18.5.2 REVENUE ANALYSIS
18.5.3 GEOGRAPHIC PRESENCE
18.5.4 PRODUCT PORTFOLIO
18.5.5 RECENT DEVELOPMENTS
18.6 PFIZER
18.6.1 COMPANY OVERVIEW
18.6.2 REVENUE ANALYSIS
18.6.3 GEOGRAPHIC PRESENCE
18.6.4 PRODUCT PORTFOLIO
18.6.5 RECENT DEVELOPMENTS
18.7 JOHNSON & JOHNSON
18.7.1 COMPANY OVERVIEW
18.7.2 REVENUE ANALYSIS
18.7.3 GEOGRAPHIC PRESENCE
18.7.4 PRODUCT PORTFOLIO
18.7.5 RECENT DEVELOPMENTS
18.8 COSETTE PHARMACEUTICALS, INC.
18.8.1 COMPANY OVERVIEW
18.8.2 REVENUE ANALYSIS
18.8.3 GEOGRAPHIC PRESENCE
18.8.4 PRODUCT PORTFOLIO
18.8.5 RECENT DEVELOPMENTS
18.9 LUPIN
18.9.1 COMPANY OVERVIEW
18.9.2 REVENUE ANALYSIS
18.9.3 GEOGRAPHIC PRESENCE
18.9.4 PRODUCT PORTFOLIO
18.9.5 RECENT DEVELOPMENTS
18.9.6 MYLAN N.V.
18.9.7 COMPANY OVERVIEW
18.9.8 REVENUE ANALYSIS
18.9.9 GEOGRAPHIC PRESENCE
18.9.10 PRODUCT PORTFOLIO
18.9.11 RECENT DEVELOPMENTS
18.1 WOCKHARDT
18.10.1 COMPANY OVERVIEW
18.10.2 REVENUE ANALYSIS
18.10.3 GEOGRAPHIC PRESENCE
18.10.4 PRODUCT PORTFOLIO
18.10.5 RECENT DEVELOPMENTS
18.11 TOLMAR PHARMACEUTICALS, INC.
18.11.1 COMPANY OVERVIEW
18.11.2 REVENUE ANALYSIS
18.11.3 GEOGRAPHIC PRESENCE
18.11.4 PRODUCT PORTFOLIO
18.11.5 RECENT DEVELOPMENTS
18.12 AKORN, INCORPORATED
18.12.1 COMPANY OVERVIEW
18.12.2 REVENUE ANALYSIS
18.12.3 GEOGRAPHIC PRESENCE
18.12.4 PRODUCT PORTFOLIO
18.12.5 RECENT DEVELOPMENTS
18.13 TELIGENT
18.13.1 COMPANY OVERVIEW
18.13.2 REVENUE ANALYSIS
18.13.3 GEOGRAPHIC PRESENCE
18.13.4 PRODUCT PORTFOLIO
18.13.5 RECENT DEVELOPMENTS
18.14 GLENMARK PHARMACEUTICAL INC.
18.14.1 COMPANY OVERVIEW
18.14.2 REVENUE ANALYSIS
18.14.3 GEOGRAPHIC PRESENCE
18.14.4 PRODUCT PORTFOLIO
18.14.5 RECENT DEVELOPMENTS
18.15 XIROMED
18.15.1 COMPANY OVERVIEW
18.15.2 REVENUE ANALYSIS
18.15.3 GEOGRAPHIC PRESENCE
18.15.4 PRODUCT PORTFOLIO
18.15.5 RECENT DEVELOPMENTS
18.16 AMNEAL PHARMACEUTICALS LLC
18.16.1 COMPANY OVERVIEW
18.16.2 REVENUE ANALYSIS
18.16.3 GEOGRAPHIC PRESENCE
18.16.4 PRODUCT PORTFOLIO
18.16.5 RECENT DEVELOPMENTS
18.17 ENCUBE ETHICALS
18.17.1 COMPANY OVERVIEW
18.17.2 REVENUE ANALYSIS
18.17.3 GEOGRAPHIC PRESENCE
18.17.4 PRODUCT PORTFOLIO
18.17.5 RECENT DEVELOPMENTS
18.18 INGENUS PHARMACEUTICALS, LLC
18.18.1 COMPANY OVERVIEW
18.18.2 REVENUE ANALYSIS
18.18.3 GEOGRAPHIC PRESENCE
18.18.4 PRODUCT PORTFOLIO
18.18.5 RECENT DEVELOPMENTS
18.19 ALEOR DERMACEUTICALS LIMITED
18.19.1 COMPANY OVERVIEW
18.19.2 REVENUE ANALYSIS
18.19.3 GEOGRAPHIC PRESENCE
18.19.4 PRODUCT PORTFOLIO
18.19.5 RECENT DEVELOPMENTS
18.2 SANDOZ AG
18.20.1 COMPANY OVERVIEW
18.20.2 REVENUE ANALYSIS
18.20.3 GEOGRAPHIC PRESENCE
18.20.4 PRODUCT PORTFOLIO
18.20.5 RECENT DEVELOPMENTS
18.21 ENCORE DERMATOLOGY, INC.,
18.21.1 COMPANY OVERVIEW
18.21.2 REVENUE ANALYSIS
18.21.3 GEOGRAPHIC PRESENCE
18.21.4 PRODUCT PORTFOLIO
18.21.5 RECENT DEVELOPMENTS
18.22 ZYDUS PHARMACEUTICALS, INC.
18.22.1 COMPANY OVERVIEW
18.22.2 REVENUE ANALYSIS
18.22.3 GEOGRAPHIC PRESENCE
18.22.4 PRODUCT PORTFOLIO
18.22.5 RECENT DEVELOPMENTS
18.23 TEVA PHARMACEUTICALS USA, INC.
18.23.1 COMPANY OVERVIEW
18.23.2 REVENUE ANALYSIS
18.23.3 GEOGRAPHIC PRESENCE
18.23.4 PRODUCT PORTFOLIO
18.23.5 RECENT DEVELOPMENTS
18.24 STIEFEL LABORATORIES, INC.
18.24.1 COMPANY OVERVIEW
18.24.2 REVENUE ANALYSIS
18.24.3 GEOGRAPHIC PRESENCE
18.24.4 PRODUCT PORTFOLIO
18.24.5 RECENT DEVELOPMENTS
18.25 SIGMAPHARM LABORATORIES, LLC.
18.25.1 COMPANY OVERVIEW
18.25.2 REVENUE ANALYSIS
18.25.3 GEOGRAPHIC PRESENCE
18.25.4 PRODUCT PORTFOLIO
18.25.5 RECENT DEVELOPMENTS
18.26 THE DAAVLIN COMPANY
18.26.1 COMPANY OVERVIEW
18.26.2 REVENUE ANALYSIS
18.26.3 GEOGRAPHIC PRESENCE
18.26.4 PRODUCT PORTFOLIO
*NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
19 RELATED REPORTS
20 CONCLUSION
21 QUESTIONNAIRE
22 ABOUT DATA BRIDGE MARKET RESEARCH
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
